Brief: Cytrx highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions
12/10/2017 14:00
Oct 12 (Reuters) - Cytrx Corp CYTR.O :
* Cytrx Corporation highlights inclusion of aldoxorubicin in
pending upcoming clinical trial submissions planned by Licensee
Nantcell, Inc.
Source text for Eikon: ID:nPn3TM9fwa
Further company coverage: CYTR.O
((bangalore.newsroom@thomsonreuters.com;))
Recent news on LadRx
See all newsBrief: Ladrx Issues 2024 Update To Shareholders
Brief: LadRx Completes Non-Dilutive Financing Transaction For Up To $11 Mln With Xoma Corporation
Brief: LadRx Intends To Apply To List Stock On Nasdaq Under Symbol 'LADX'
Brief: LadRx Announces Review Of Strategic Alternatives, Provides Corporate Updates
Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C